US12453778 — Incremental dose finding in controlled-release PTH compounds
Method of Use · Assigned to Ascendis Pharma Bone Diseases AS · Expires 2037-09-28 · 11y remaining
What this patent protects
This patent protects a method of using a controlled-release PTH compound to treat conditions that can be treated with PTH, with dose adjustments made in increments of no more than 25% in response to hypocalcemia or hypercalcemia.
USPTO Abstract
The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%.
Drugs covered by this patent
- Yorvipath (PALOPEGTERIPARATIDE) · Ascendis Pharma Bone
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3982 |
— | Yorvipath |
U-3982 |
— | Yorvipath |
U-3982 |
— | Yorvipath |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.